Potential renoprotective effects of silymarin against nephrotoxic drugs: A review of literature

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 15, Issue 1, 2012, Pages 112-123

  Shahbazi, Foroud ^a   Dashti Khavidaki, Simin ^a   Khalili, Hossein ^a   Lessan Pezeshki, Mahboob ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMINOGLYCOSIDE ANTIBIOTIC AGENT; CISPLATIN; CYCLOSPORIN; DOXORUBICIN; GENTAMICIN; PARACETAMOL; QUERCETIN; SILIBININ; SILICRISTIN; SILYBUM MARIANUM EXTRACT; SILYMARIN; VINCRISTINE;

ACUTE KIDNEY FAILURE; ADVERSE OUTCOME; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; BREAST CANCER; CARDIOTOXICITY; CELL PROLIFERATION; CHRONIC KIDNEY FAILURE; COLON CANCER; COMBINATION CHEMOTHERAPY; CREATININE CLEARANCE; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; ENZYMURIA; FANCONI RENOTUBULAR SYNDROME; GLOMERULUS FILTRATION RATE; HEAD CANCER; HODGKIN DISEASE; HORMONE DEFICIENCY; HUMAN; HYPERURICEMIA; HYPOCALCEMIA; HYPOMAGNESEMIA; INTERMETHOD COMPARISON; KIDNEY CARCINOMA; KIDNEY DISEASE; KIDNEY TUBULE ACIDOSIS; LIPID PEROXIDATION; LUNG CANCER; MONOTHERAPY; NECK CANCER; NEOPLASM; NEPHROTOXICITY; NONHUMAN; OVARY CANCER; PROSTATE CANCER; PROTEINURIA; RENAL PROTECTION; SALT WASTING; SKIN CANCER; TESTIS CANCER; THROMBOTIC THROMBOCYTOPENIC PURPURA; TUBULAR DYSFUNCTION; UREA NITROGEN BLOOD LEVEL;

EID: 84856799480     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/J3F88S     Document Type: Article

References (46)

1. Dolin, TD. and Himmelfarb, J., Drug-induced kidney disease, in Dipiro JT(eds), Pharmacotherapy, a pathophysiologic approach, 7th ed., Mc Graw Hill companies Inc,New York, pp 795-810, 2008.
2. Cynthia A. Naughton. Drug-Induced Nephrotoxicity. Am Fam Physician, 78:743-750,2008.
3. Vladimir Kren, Daniela Walterova. Silybin and silymarin- new effects and applications. Biomed Papers, 149(1):29-41, 2005.
4. Ludovico Abenavoli, Raffaele Capasso, Natasa Milic, Francesco Capasso. Milk thistle in liver disease: past, present, future. Phytother Res, 24(10): 1423-1432, 2010.
5. Carmela Loguerico, Davide Festi. Silybin and the liver: from basic research to clinical practice. World J Gastroenterol, 17(18): 2288-2301,2011.
6. Reinhard Saller, Remy Meier, Reto Brignoli. The use of silymarin in the treatment of liver diseases. Drugs. 61(14): 2035-2063, 2001.
7. Mudit Vaid, Santosh K. Katiyar. Molecular mechanisms of inhibition of photocarcinogenesis by silymarin, a phytochemical from milk thistle (Silybum marianum L. Gaertn)(Review). Int Journal Oncol, 36(5): 1053-1060, 2010.
8. Johann Sonnenbichler, Fortunato Scalera, Isolde Sonnenbichler, Roland Weyhenmeyer. Stimulating effects of silibinin and silicristin from themilk thistle Silybum marianum on kidney cells. J Pharm Exp Ther, 290: 1375-1383, 1999.
9. Ronald P Miller, Raghu K Tadagavadi, Ganesan Ramesh, William Brain Reeves. Mechanisms of cisplatin nephrotoxicity. Toxins, 2: 2490-2518, 2010.
10. N Pabla N, Z Dong. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int, 73(9):994-1007,2008.
11. Fumie Shiraishi, Lisa M. Curtis, Leigh Truong, Kenneth Poss, Gary A. Visner, Kirsten Madasen, Harry S. Nick, Anupam Agarwal. Heme oxygenase- 1 gene ablation or expression modulates cisplatininduced renal tubuar apoptosis. Am J Physiol Renal Physiol, 278: F726-F736, 2000.
12. Christopher A. Dasis, Harry S. Nick, Anupam Agarwal. Manganese superoxide dismutase attenuates cisplatin-induced renal injury: importance of superoxide. J Am Soc Nephrol, 12: 2683-2690, 2001.
13. Ganesan Ramesh, William Brain Reeves. P38 MAP kinase inhibition ameliorates cisplatin nephrotoxicity in mice. Am J Physiol Renal Physiol, 289: F166-F174,2005.
14. J Gaedeke, LM Fels, C Bokemeyer, U Mengs, H Stolte, H Lentzen. Cisplatin nephrotoxicity and protection by silibinin. Nephrol Dial Transplant, 11:55-62,1996.
15. C Bokemeyer, L.M Fels, T Dunn, W Voigt, J Gaedeke, H-J Schmoll, H Stolte, H Lentzen. Silibinin protects against cisplatin-induced nephrotoxicity without compromising cisplatin or ifosphamide anti-tumor activity. Br J Cancer, 74: 2036-2041,1996.
16. Gholamreza Karimi, Mohammad Ramezani, Zahra Tahoonian. Cisplatin nephrotoxicity and protection by milk thistle extract in rats. Evid Based Complement Alternat Med, 2:383-386, 2005.
17. Nabia E. Abdelmeguid, Hania N. Chmaisse, Noura S. Abou Zeinab. Protective effect of silymarin on cisplatin-induced nephrotoxicity in rats. Pakistan Journal of Nutrition, 9(7):624-636, 2010.
18. Estela B. Behling, Milena C. Sendao, Heloisa D.C. Francescato, Lusania M.G. Antunes, Roberto S. Costa, Maria de Lourdes P. Bianchi. Comparative study of multiple dosage of quercetin against cisplatin-induced nephrotoxicity in rat kidney. Pharmacol Rep, 58:526-532, 2006.
19. Penelope D. Sanchez-Gonzalez, Francisco J. Lopez-Hernandez, Fernando Perez-Barricanal, Ana I. Morales, Jose M. Lopez-Novoa. Quercetin reduces cisplatin nephrotoxicity in rats without compromising its anti-tumor activity. Nephrol Dial Transplant, 26(11):3484-3495, 2011.
20. Valentina Colombo, Monica Lupi, Francesca Falcetta, Daniele Forestieri, Maurizio D'Incalci, Paolo Ubezio. Chemotherapeutic activity of silymarin combined with doxorubicin or paclitaxel in sensitive and multidrug-resstant colon cancer cells. Cancer Chemother Pharmacol, 67:369-379, 2011.
21. Catherine Wing Ying Cheung, Norma Gibbons, David Wayne Johnson, David Lawrence Nicol. Silibinin-A promising new treatment for cancer. Anticancer Agents Med Chem, 10(3): 186-195, 2010.
22. Chuanpit Ninsontia, Kanittha Pongjit, Chatchai Chaotham, Pithi Chanvorachote. Silymarin selectively protects human renal cells from cisplatininduced cell death. Pharm Biol, 49(10):1082-1090, 2011.
23. Nagla A. El-Shitany, Sahar El-Haggar, Karema El- Desoky. silymarin prevents adriamycin-induced cardiotoxicity and nephrotoxicity in rats. Food Chem Toicol, 46: 2422-2428, 2008.
24. Jose M. Lopez-Novoa, Yaremi Quiros, Laura Vicente, Ana I. Morales, Francisco J. Lopez- Hernandez. New insight into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view. Kidney Int, 79: 33-45, 2011.
25. H.N. Varzi, S Esmailzadeh, H Morovvati, R Avizeh, A Shahriari, M.E. Givi. Effect of silymarin and vitamin E on gentamicin-induced nephrotoxicity. J Vet Pharmacol Therap, 30: 477-481, 2007.
26. Maarten Naesens, Dirk R.S. Kuypers, Minnie Sarwal. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol, 4: 481-508, 2009.
27. Tom AS Zima, Ludmila Kamenikova, Marta Janebova, Evzen Buchar, Jirina Crkovska, Vladimir Tesar. The effect of silibinin on experimental cyclosporine nephrotoxicity. Ren Fail, 20(3): 471-479, 1998.
28. P.S.V. Satayanarayana, D. Singh, K. Chopra. Quercetin, a bioflavonoid, protects against oxidative stress-related renal dysfunction by cyclosporine in rats. Methods Find Exp Clin Pharmacol, 4: 175-181, 2001.
29. www.Uptodate.com, 19.3.
30. Vinayagam Ramachandran, Ramalingam Sarvanan, Boobalam Raja. Attenuation of oxidative stress by syringic acid on acetaminophen-induced nephrotoxic rats. Comp Clin Path, DOI 10.1007/s00580-011-1327-z,2010.
31. Nitin Dixit, Sanjula Baboota, Kanchan Kohli, S. Ahmad, Javed Ali. Silymarin: A review of pharmacological aspects and bioavailability enhancement approaches. Indian J Pharmacol, 39: 172-179, 2007.
32. Jamshid Roozbeh, Bahram Shahriyari, Masoumeh Akmali, Ghazal Vessal, Maryam Pakfetrat, Ghanbar Ali Raees Jalali, Raha Afshariani, Mahshid Hasheminasab, Nasrollah Ghahramani. Comparative effects of silymarin and vitamin E supplementation on oxidative stress markers, and hemoglobin levels among patients on hemodialysis. Ren Fai, 33(2): 118-123, 2011.
33. C. Soto, J. Perez, V. Garcia, E. Uria, M. Vadillo, L. Raya. Effects of silymarin on kidneys of rats suffering from alloxan-induced diabetes mellitus. Phytomedicine,17: 1090-1094,2010.
34. Ghazal Vessal, Masoumeh Akmali, Parisa Najafi, Mahmood Reza Moein, Mohmmad Mahdi Sagheb. Silymarin and milk thistle may prevent the progression of dibatic nephropathy in streptozotocin-induced diabetic rats. Ren Fail, 32: 733-739, 2010.
35. Muhammad Rashid Khan, Fatima Siddique. Antioxidant effectsof Citharexylum spinosum in CCl4 induced nephrotoxicity in rat. Exp Toxicol Pathol, DOI:10.1016/j.etp.2010.09.009,2010.
36. Gurpeet Kaur, Mohammad Athar, M. Sarwar Alam. Dietary supplementation of silymarin protects against chemically induced nephrotoxicity, inflammation and renal tumor promotion response. Invest New Drugs, 28:703-713, 2010.
37. Eduardo Homsi, Silvano Machado de Brito, Patricia Janino. Silymarin exacerbates p53-mediated tubular apoptosis in glycerol-induced acute kidney injury. Ren Fail, 32:623-632, 2010.
38. Hakan Senturk, Sahin Kabay, Gokhan Bayramoglu, Hilmi Ozden, Faik Yaylak, Mehmet Yucel, esra Gurlek Olgun, Ali Kutlu. Silymarin attenuates the renal ischemia/reperfusion injury-related morphological changes in the rat kidney. World j Urol, 26: 401-407, 2008.
39. Faruk Turgut, Omer Bayrak, Farhat Catal, Reyhan Bayrak, Ali Fuat Atmaca, Akif Koc, Ali Akbas, Ali Akcay, Dogan Unal. Antioxidant and protective effects of silymarin on ischemia and reperfusion injury in the kidney tissues of rats. Int Urol Nephrol, 40:453-460, 2008.
40. Horng-Rong Chang, Pei-Ni Chen, Shun-Fa Yang, Ying-Sui Sun, Sheng-Wen Wu, Tung-Wei Hung, Jong-Da Lian, Shu-Chen Chu, Yih-Shou Hsieh. Silibinin inhibits the invasion and migration of renal carcinoma 786-O cells in vitro, inhibits the growth of xenografts in vivo and enhances chemosensitivity to 5-fluorouracil and paclitaxel. Mol Carcinog, 50(10):811-823, 2011.
41. Lei Li, Ye Gao, Linlin Zhang, Jin Zeng, Dalin He, Yi Sun. Silibinin inhibits cell growth and induces apoptosis by caspase activation, down-regulating survivin and blocking EGFR-ERK activation in renal cell carcinoma. Cancer Lett, 272: 61-69, 2008.
42. Jhy-Wen Wu, Li-Chwen Lin, Tung-Hu Tsai. Drugdrug interactions of silymarin on the perspective of pharmacokinetics. J Ethnopharmacol, 121: 185-193, 2009.
43. Yang Han, Dong Guo, Yao Chen, Yu Chen, Zhi- Rong Tan, Hong-Hao Zhou. Effect of silymarin on the pharmacokinetic of losartan and its active metabolite E-3174 in healthy Chinese volunteers. Eur J Clin Pharmacol, 65: 585-591, 2009.
44. Jiaan Wein Deng, Ji-Hong Shon, Ho-Jung Shin, Soo-Jin Park, Chang-Woo Yeo, Hong-Hao Zhou, Im-Sook Song, Jae-Gook Shin. Effect of silymarin supplement on the pharmacokinetic of rosuvastatin. Pharm Res, 25:1807-1814, 2008.
45. A. Ghosh, T. Ghosh, S. Jain. Silymarin-areview on pharmacodynamics and bioavailability enhancement approaches. J Pharm Sci Technol, 2(10): 348-355, 2010.
46. Gholamreza Karimi, Maryam Vahabzadeh, Paisa Lari, Marziyeh Rashedinia, Mohammad Moshiri. "Silymarin", a promising pharmacological agent for treatment of diseases. Iranian Journal of Basic Medical Sciences, 14(4): 308-317, 2011.